NEW YORK (Reuters) – Abbott Laboratories Inc said its third-quarter profit rose 37 percent on strong demand for its Humira arthritis drug and nutritional products, as well as gains from a settlement with Medtronic Inc .

Credit:
Abbott profit up on Humira demand, special gain